2nd Annual Pharmassist Seminar – Athens, Greece

Economic Evaluation of Health Technologies for Pricing & Reimbursement Purposes

Health Economics, Economic Evaluation in Health Care, Drug Pricing and Reimbursement, Micro and Macroeconomic Analysis of Pharmaceutical Expenditures, Health Technology Assessment

Who should attend

Directors, Heads, Managers, Officers & Personnel of:

Pricing and Reimbursement, Market Access, Health Economics, Finance, Economics and Government Affairs, Business Strategy, Sales & Marketing, Brand Management, Corporate Strategy, Operations, Regulatory Affairs, Public Relations & Affairs, Outcomes Research, Contracts, Legal, Health Policy Advisors

Download Brochure

Day 1 - Events Timetable

09:00 – 09:30 REGISTRATION – ATTENDANCE
09:30 – 09:40 WELCOME – OPENING REMARKS
09:40 – 10:15 INTRODUCTION TO ECONOMIC EVALUATION OF HEALTH CARE AND ITS ROLE IN THE DECISION-MAKING AND HEALTH POLICY
10:15 – 11:00 METHODS OF ECONOMIC EVALUATION ANALYSIS I
11:00 – 11:30 COFFEE BREAK
11:30 – 12:15 METHODS OF ECONOMIC EVALUATION ANALYSIS II
12:15 – 13:00 THE ROLE OF HTA ORGANIZATIONS AND THE DEVELOPMENT OF CLINICAL GUIDELINES. Presentation of the National Institute of Clinical Excellence (NICE) technology appraisal process and the NHS-Economic Evaluation Database of the University of York – UK
13:00 – 13:30 DISCUSSION QUESTIONS AND DEBATE
13:30 – 15:00 LUNCH BREAK
15:00 – 15:45 HANDLING UNCERTAINTY IN ECONOMIC EVALUATION. Methodological issues and constraints
15:45 – 16:30 UTILIZATION OF EPIDEMIOLOGICAL, CLINICAL AND ECONOMIC DATA Evidence based medicine (EBM) assessment. Application of economic evaluation case studies and modeling techniques
16:30 – 17:00 DISCUSSION QUESTIONS AND DEBATE

Day 2 - Events Timetable

09:00 – 09:15 ATTENDANCE
09:30 – 10:15 PRICING AND REIMBURSEMENT IN HEALTH CARE: Reimbursement models in EU countries
10:15 – 11:00 STRATEGIES OF EUROPEAN HEALH CARE SYSTEMS: Market Access and reimbursement pathways
11:00 – 11:30 COFFEE BREAK
11:30 – 12:15 MICRO AND MACROECONOMIC ANALYSIS OF PHARMACEUTICAL EXPENDITURE The potential economic impact of HTA on rational decision making and on healthy policy and economics
12:15 – 13:00 THE IMPACT OF ECONOMIC EVALUATION AND HTA ON THE DEVELOPMENT PROCESS; The Spanish perspective
13:00 – 13:30 DISCUSSION QUESTIONS AND DEBATE
13:30 – 15:00 LUNCH BREAK
15:00 – 15:45 HEALTH TECHNOLOGY ASSESSMENT; The Pharma industry perspective
15:45 – 16:15 DISCUSSION QUESTIONS AND DEBATE Recent developments and future challenges for economic evaluation methods in health care
16:15 – 16:30 CLOSING REMARKS

Event Speakers

Mary Geitona

As. Professor of Health Economics, University of Peloponnese, President of Greece ISPOR chapter

Angeliki Angeli MSc.

Health Economist Sanofi-Aventis

Oriol Sola-Morales

Medical Director Sabirmedical S.L. Barcelona, Spain

John Yfantopoulos

Prof. of Health Economics University of Athens, Greece

Isabel Henkel

Director Market Access & Reimbursement JnJ, Germany

Maria Raikou Ph.D

Health Economist LSE, Lecturer

Dimitra Labreli Ph.D

Health Economist, UnitedBiosource (UBC) London

Magda Hatzikou Ph.D

Health Economist, Novartis Hellas

Ioanna Koukli Ph.D

General Manager Pharmassist LTD